Value of European outsourcing today

- Last updated on GMT

Related tags: Pharmacology, European union, United kingdom

"Tremendous advances in science and technology, along with the
shrinking period for patent exclusivity, are creating unprecedented
opportunities for the drug development industry," said a CEO
this week while discussing the value of outsourcing.

"Tremendous advances in science and technology, along with the shrinking period for patent exclusivity, are creating unprecedented opportunities for the drug development industry,"​ said chairman and CEO of Kendle International​ Dr. Candace Kendle this week, speaking at the 2003 European "Partnerships in Clinical Trials" conference.

Addressing representatives from the pharmaceutical and biotechnolgy industries in Lyon, France, Kendle focused on key issues affecting the global drug development marketplace, including optimising successful partnerships between outsourcing providers and sponsors and the role of CROs in helping to progress clinical research.

"In this environment where speed-to-market has never been more important, pharmaceutical and biotechnology companies are relying increasingly on outsourcing providers to create efficiencies and ultimately help them get new drugs to market faster,"​ added Kendle.

The US company has a network of European operations, with nine locations and approximately one-third of its workforce located throughout the United Kingdom, Italy, Germany, France, The Netherlands, Poland and Spain. Approximately 25 per cent of the company's 2002 revenue was generated in Europe.

Related topics: Ingredients

Related news

Follow us

Products

View more

Webinars